<DOC>
	<DOCNO>NCT01224210</DOCNO>
	<brief_summary>This Open Label , Multicenter , pilot clinical trial ass efficacy safety oral selective Endothelin Receptor Antagonist ( ambrisentan ) patient portopulmonary hypertension . Preliminary evidence suggest ambrisentan safe effective patient portopulmonary hypertension . The goal therapy patient improve symptom dyspnea improve pulmonary hemodynamics mean pulmonary artery pressure &lt; 35 mm Hg order make patient eligible liver transplantation . Therefore , primary endpoint study include 6 minute walk distance ( 6MWD ) pulmonary vascular resistance ( PVR ) . Eligible subject receive 5 mg ambrisentan once-daily first 4 week . After initial 4-week period , investigator increase study drug dose 10 mg daily ( 5 mg 10 mg dos FDA approve ) . If 10 mg tolerate opinion investigator , investigator may decrease dose back 5 mg daily . Primary outcome change 6MWD PVR baseline Week 24 . Subjects monitor liver function test ( LFT ) every 2 week first 8 week , every 4 week thereafter . These safety laboratory test may perform local phlebotomy laboratory Investigator clinic . In addition , Investigator ass subject safety efficacy Week 4 , Week 12 , Week 24 . Following Week 24 , subject assess safety efficacy every 12 week . Patients follow total 1 year . After 1 year , Investigator feel continue treatment beneficial patient , provide ambrisentan Gilead Pharmaceuticals , free charge .</brief_summary>
	<brief_title>Ambrisentan Patients With Porto-pulmonary Hypertension A Multicenter Open Label Trial</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Endothelin Receptor Antagonists</mesh_term>
	<criteria>Subjects need fulfill follow 4 criterion : 1 . Evidence portal hypertension ( hemodynamic measurement , Doppler flow portal circulation , clinical evidence portal hypertension esophageal gastric varix , evidence prior upper endoscopy ) . 2 . Evidence pulmonary arterial hypertension right heart catheterization ( three criterion need present ) Right heart catheterization may perform 30 day prior screen Mean PAP ( pulmonary artery pressure ) &gt; 25 mm Hg , PVR ( pulmonary vascular resistance ) &gt; 240 dynes/s/cm5 , TPG ( transpulmonary gradient = meanPAP PAWP ) &gt; 12 mm Hg 3 . Baseline AST , ALT &lt; 5 time upper limit normal , total Bili &lt; 3.0 mg/dl , mild liver impairment Child Pugh class A B 4 . Ages 18 year 1 . Presence etiology pulmonary arterial hypertension ( HIV , connective tissue disease , sickle cell , leave heart failure , chronic thromboembolic PH , etc ) 2 . Treatment prostacyclins , ERAs , PDE5 inhibitor within 30 day enrollment . 3 . Moribund state anticipate death within 1 month . 4 . AST ALT ≥ 5 time upper limit normal 5 . Total bilirubin ≥ 3.0 mg/dl 6 . Significant lung disease ( obstructive lung disease FEV1 &lt; 1L , FEV1/FVC &lt; 50 % ; restrictive lung disease Total Lung Capacity &lt; 60 % predict ) . PFTs may perform 6 month prior enrollment . 7 . Pregnancy 8 . Age &lt; 18 year 9 . Child Pugh class C</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>portopulmonary hypertension</keyword>
	<keyword>portal hypertension</keyword>
	<keyword>esophageal gastric varix</keyword>
	<keyword>right heart catheterization</keyword>
	<keyword>transpulmonary gradient</keyword>
	<keyword>Endothelin Receptor Antagonist</keyword>
	<keyword>Ambrisentan</keyword>
	<keyword>Letairis</keyword>
	<keyword>pulmonary hemodynamics</keyword>
</DOC>